YU46903A - Derivati difenil-azetidinona,postupak za njihovu proizvodnju lekovi koji sadrže ova jedinjenja i njihova primena - Google Patents

Derivati difenil-azetidinona,postupak za njihovu proizvodnju lekovi koji sadrže ova jedinjenja i njihova primena

Info

Publication number
YU46903A
YU46903A YU46903A YUP46903A YU46903A YU 46903 A YU46903 A YU 46903A YU 46903 A YU46903 A YU 46903A YU P46903 A YUP46903 A YU P46903A YU 46903 A YU46903 A YU 46903A
Authority
YU
Yugoslavia
Prior art keywords
compounds
production
medicaments containing
azetidinone derivatives
diphenyl azetidinone
Prior art date
Application number
YU46903A
Other languages
English (en)
Serbo-Croatian (sh)
Inventor
Heiner Glombik
Werner Kramer
Stefanie Flohr
Wendelin Frick
Hubert Heuer
Gerhard Jaehne
Andreas Lindenschmidt
Hans-Ludwig Schaefer
Original Assignee
Aventis Pharma Deutschland Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10064402A external-priority patent/DE10064402A1/de
Priority claimed from DE2001154520 external-priority patent/DE10154520A1/de
Application filed by Aventis Pharma Deutschland Gmbh. filed Critical Aventis Pharma Deutschland Gmbh.
Publication of YU46903A publication Critical patent/YU46903A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
YU46903A 2000-12-21 2001-12-11 Derivati difenil-azetidinona,postupak za njihovu proizvodnju lekovi koji sadrže ova jedinjenja i njihova primena YU46903A (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10064402A DE10064402A1 (de) 2000-12-21 2000-12-21 Diphenylazetidinonderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE2001154520 DE10154520A1 (de) 2001-11-07 2001-11-07 Diphenylazetidinonderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung

Publications (1)

Publication Number Publication Date
YU46903A true YU46903A (sh) 2006-05-25

Family

ID=26008045

Family Applications (1)

Application Number Title Priority Date Filing Date
YU46903A YU46903A (sh) 2000-12-21 2001-12-11 Derivati difenil-azetidinona,postupak za njihovu proizvodnju lekovi koji sadrže ova jedinjenja i njihova primena

Country Status (23)

Country Link
US (1) US6498156B2 (enExample)
EP (1) EP1345932B1 (enExample)
JP (1) JP2004516293A (enExample)
KR (1) KR20030061462A (enExample)
CN (1) CN1222522C (enExample)
AR (1) AR034282A1 (enExample)
AT (1) ATE342899T1 (enExample)
AU (2) AU2002219173B2 (enExample)
BR (1) BR0116482A (enExample)
CA (1) CA2431985A1 (enExample)
CZ (1) CZ20031731A3 (enExample)
DE (1) DE50111293D1 (enExample)
EE (1) EE200300237A (enExample)
HR (1) HRP20030499A2 (enExample)
HU (1) HUP0401067A2 (enExample)
IL (1) IL156552A0 (enExample)
MX (1) MXPA03005018A (enExample)
NO (1) NO20032733L (enExample)
NZ (1) NZ526592A (enExample)
PL (1) PL362173A1 (enExample)
SK (1) SK7812003A3 (enExample)
WO (1) WO2002050068A1 (enExample)
YU (1) YU46903A (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
CN1217927C (zh) * 2000-12-21 2005-09-07 阿文蒂斯药物德国有限公司 新的1,2－二苯基氮杂环丁烷酮、其制备方法、含有所述化合物的药物及其在治疗脂质代谢病症中的应用
AR034204A1 (es) * 2001-01-26 2004-02-04 Schering Corp Composiciones y combinaciones de acido nicotinico y derivados del mismo con inhibidor(es) de la absorcion de los esteroles, y el uso de los mismos para preparar medicamentos para el tratamiento para indicaciones vasculares
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
ES2296894T3 (es) * 2001-01-26 2008-05-01 Schering Corporation Combinaciones de ezetimiba con aspirina para tratar estados vasculares.
RU2756946C2 (ru) 2001-01-26 2021-10-07 Мерк Шарп И Доум Корп. Применение замещенных азетидинонов для лечения ситостеролемии
ATE369851T1 (de) * 2001-01-26 2007-09-15 Schering Corp Kombinationen von gallensäuresequestriermitteln und hemmern der sterolabsorption zur behandlung von kardiovaskulären indikationen
AU2002247019C1 (en) * 2001-01-26 2017-05-11 Organon Llc Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
CN1582168A (zh) * 2001-01-26 2005-02-16 先灵公司 用于治疗血管性疾病的固醇吸收抑制剂与心血管药剂的组合
EP1425018B1 (de) * 2001-08-22 2008-10-22 Sanofi-Aventis Deutschland GmbH Kombinationspräparate von 1,4- benzothiepin-1,1-dioxidderivaten mit weiteren wirkstoffen und deren verwendung
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
DE60216300T2 (de) 2001-09-21 2007-06-28 Schering Corp. Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
US7671047B2 (en) 2002-06-19 2010-03-02 Sanofi-Aventis Deutschland Gmbh Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176194B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
DE10227507A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227508A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US7176193B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
AU2003254261B2 (en) * 2002-07-30 2008-04-17 Children's Medical Center Corporation Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors
CA2504878A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
MXPA05009501A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
EP1601668B1 (en) 2003-03-07 2008-08-27 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
MXPA05009502A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
JP5172146B2 (ja) * 2003-05-09 2013-03-27 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 癌を標的化するための組成物及び方法
US20070072812A1 (en) * 2003-08-25 2007-03-29 Microbia, Inc. Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
JP4688819B2 (ja) 2003-12-23 2011-05-25 アストラゼネカ アクチボラグ コレステロール吸収阻害活性を有するジフェニルアゼチジノン誘導体
CA2553985A1 (en) * 2004-01-20 2005-07-28 Panacea Biotec Ltd. Pharmaceutical compositions comprising higher primary alcohols and ezetimibe and process of preparation thereof
SI1725234T1 (sl) 2004-03-05 2013-04-30 The Trustees Of The University Of Pennsylvania Postopki zdravljenja nepravilnosti ali bolezni povezanih s hiperlipidemijo in hiperholesterolemijo z minimiziranjem stranskih uäśinkov
EP1807070A1 (en) * 2004-09-29 2007-07-18 Schering Corporation Combinations of substituted azetidinones and cb1 antagonists
EP1809619A1 (en) * 2004-10-21 2007-07-25 Transtech Pharma, Inc. Bissulfonamide compounds as agonists of galr1, compositions, and methods of use
NZ555320A (en) 2004-12-03 2010-11-26 Schering Corp Substituted piperazines as CB1 antagonists
TW200726746A (en) 2005-05-06 2007-07-16 Microbia Inc Processes for production of 4-biphenylylazetidin-2-ones
WO2006122117A2 (en) * 2005-05-09 2006-11-16 Microbia, Inc. Organometal benzenephosphonate coupling agents
KR20080017345A (ko) * 2005-05-11 2008-02-26 마이크로비아 인코포레이티드 페놀성 4-비페닐일아제티딘-2-온의 제조방법
US20090099355A1 (en) * 2005-05-25 2009-04-16 Microbia, Inc. Processes for Production of 4-(Biphenylyl)Azetidin-2-One Phosphonic Acids
EP1902046B1 (en) * 2005-06-20 2009-12-02 Schering Corporation Piperidine derivatives useful as histamine h3 antagonists
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
US20070088089A1 (en) * 2005-10-18 2007-04-19 Wisler Gerald L Methods for treating disorders associated with hyperlipidemia in a mammal
US7897601B2 (en) * 2006-01-18 2011-03-01 Intervet, Inc. Cannabinoid receptor modulators
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
EP2059241A1 (en) * 2006-09-05 2009-05-20 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
WO2008039829A2 (en) * 2006-09-26 2008-04-03 Ironwood Pharmaceuticals, Inc. Diphenylheterocycle cholesterol absorption inhibitors
DE102007002260A1 (de) * 2007-01-16 2008-07-31 Sanofi-Aventis Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
CN101796033A (zh) * 2007-06-28 2010-08-04 英特维特国际股份有限公司 作为cb1拮抗剂的取代的哌嗪
CN101790521A (zh) * 2007-06-28 2010-07-28 英特维特国际股份有限公司 作为cb1拮抗剂的取代哌嗪
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) * 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US9212175B2 (en) 2009-03-06 2015-12-15 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
CN101993403B (zh) 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
JP2013503135A (ja) 2009-08-26 2013-01-31 サノフイ 新規な結晶性複素芳香族フルオログリコシド水和物、その化合物を含んでなる医薬及びその使用
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
CN102746249B (zh) * 2012-07-07 2013-12-25 山东诚创医药技术开发有限公司 一种依折麦布中间体的纯化精制方法
EP4188372A1 (en) 2020-07-29 2023-06-07 Amryt Pharmaceuticals Inc. Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
JPH10501811A (ja) * 1994-06-20 1998-02-17 シェーリング コーポレイション 低コレステロール化剤として有用な置換アゼチジノン化合物
ATE199718T1 (de) * 1994-09-13 2001-03-15 Monsanto Co Benzothepines mit wirkung als inhibitoren des gallensäuretransports und der taurocholate- aufnahme
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents

Also Published As

Publication number Publication date
US20020128252A1 (en) 2002-09-12
US6498156B2 (en) 2002-12-24
NZ526592A (en) 2004-11-26
AU2002219173B2 (en) 2006-06-22
SK7812003A3 (en) 2004-01-08
WO2002050068A1 (de) 2002-06-27
CN1222522C (zh) 2005-10-12
CZ20031731A3 (cs) 2003-09-17
HK1059936A1 (en) 2004-07-23
NO20032733D0 (no) 2003-06-16
AU1917302A (en) 2002-07-01
EP1345932B1 (de) 2006-10-18
BR0116482A (pt) 2004-02-03
DE50111293D1 (de) 2006-11-30
AR034282A1 (es) 2004-02-18
KR20030061462A (ko) 2003-07-18
MXPA03005018A (es) 2003-09-25
EE200300237A (et) 2003-08-15
IL156552A0 (en) 2004-01-04
HRP20030499A2 (en) 2005-04-30
NO20032733L (no) 2003-08-14
JP2004516293A (ja) 2004-06-03
HUP0401067A2 (hu) 2004-09-28
CN1481381A (zh) 2004-03-10
CA2431985A1 (en) 2002-06-27
ATE342899T1 (de) 2006-11-15
EP1345932A1 (de) 2003-09-24
PL362173A1 (en) 2004-10-18

Similar Documents

Publication Publication Date Title
YU46903A (sh) Derivati difenil-azetidinona,postupak za njihovu proizvodnju lekovi koji sadrže ova jedinjenja i njihova primena
YU47803A (sh) Derivati difenil-azetidinona, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena
YU70901A (sh) Derivati 1,4-benzotiazepin-1,1 dioksida zamenjeni radikalima šećera, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena
ZA200409379B (en) Cationically substituted diphenyl azetidinones, method for their production, medicaments containing said compounds and use thereof
TNSN04250A1 (en) Diphenyl azetidinones substituted by acidic groups, method for their production, medicaments containing said compounds and use thereof.
YU45403A (sh) Novi 1,2-difenil-azetidinoni, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena za lečenje poremećaja u metabolizmu lipida
SE0104140D0 (sv) Novel Compounds
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
MXPA04001500A (es) Compuestos que tienen un efecto sobre la glucocinasa.
GB0003154D0 (en) Novel compounds
MXPA02011458A (es) Derivados de acilfenilurea, metodos para su produccion y uso de los mismos como farmacos.
IL164002A (en) Sulfonyl-derivatives, pharmaceutical compositions comprising them for inhibiting histone deacetylase and process for their manufacture
IL164007A (en) Compounds and pharmaceutical compositions inhibiting histone deacetylase, their use and process for their manufacture
ZA200604719B (en) DPP-IV inhibitors
TNSN05244A1 (en) Novel diphenyl azetidinone with improved physiological characteristics, corresponding production method, medicaments containing said compound and use of the latter
MEP9309A (en) Novel oligosaccharides, preparation method and pharmaceutical compositions containing the same
GEP20084376B (en) Pyridopyrimidinone compounds, method for production thereof and medicaments comprising the same
GEP20084361B (en) Piperidinylcarbonyl-pyrro-lidines and their use as melanocortin agonists
SG165159A1 (en) Process for preparing 6-alkylidene penem derivatives
NZ515108A (en) Novel ribose-substituted aromatic amides, method for the production and use thereof as medicaments
GEP20063896B (en) New heterocyclic oxime compound, method for production of the same and pharmaceutical composition comprising the same
PL377293A1 (pl) Podstawione pochodne kwasu benzoiloureidopirydynylo-piperydyno- i pirolidynokarboksylowego, sposób ich wytwarzania oraz ich zastosowanie
YU83403A (sh) Korišćenje derivata piridoindolona za spravljanje lekova
PT1000952E (pt) Novos derivados 2-halogenados de 5-o-desosaminileritronolida a, processo de preparação e sua utilização como medicamentos
MXPA04001856A (es) Indan-1-oles c2-sustituidos y sus derivados, metodo para su produccion y su uso como medicamentos.